Deal Snapshot: Agios sold rights to a 15% royalty on US net sales of the IDH1/2 inhibitor vorasidenib, which it sold to Servier in 2020.
Who: Agios Pharmaceuticals and Royalty Pharma
What: Agios will monetize a royalty revenue stream by selling it to Royalty Pharma
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Rising biotech valuations mean return on investment on some deals is non-existent for big pharma, though certain strategies will improve chances of success, a new analysis has found.
Dr. Reddy's Laboratories preps for potential US tariffs, focusing on sustaining product supply and collaborating with customers on inventories. A recent US plant sale, the firm stressed, was unrelated to tariffs and underlines its openness to ‘make in the US’, where it launched 18 products in fiscal 2025.
An ‘historic economic prosperity deal’ does not include the sector.
Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’
Roche/Genentech unveiled plans for a $700m-plus manufacturing facility for weight loss drugs in North Carolina as President Trump signaled such investments could mean no tariffs for pharma.
The details of Trump’s latest executive order on drug pricing are vague and the president put more blame on other countries and pharma distributors than drug companies.
Rising biotech valuations mean return on investment on some deals is non-existent for big pharma, though certain strategies will improve chances of success, a new analysis has found.
